Establishing a familial hypercholesterolaemia register - The first year

Atheroscler Suppl. 2019 Mar:36:24-27. doi: 10.1016/j.atherosclerosissup.2019.01.005. Epub 2019 Feb 2.

Abstract

Background and aims: Familial hypercholesterolemia (FH) is an autosomal dominant condition raising the risk of premature cardiovascular disease up to twentyfold.[1] [2] It is under-diagnosed and undertreated, in spite of availability of effective treatment. Registers are recommended to assist in the recognition and improvement of the condition since treatment reduces morbidity and mortality. Disease registers enable longitudinal review and the application of continuous quality improvement methodology. The aims of this paper are to describe the process of setting up a new FH register in Malta based on phenotype, the preliminary results achieved, the barriers encountered, how these were overcome, and future plans for development.

Methods: The registry was established as an observational clinical study designed for a small healthcare system with limited resources. Effective process design requires attention to standards, capacity, outcome measurement and feedback, which have been incorporated.

Results: 43 individuals have been registered applying Dutch Lipid Clinic Network standards, including 9 Definite, 16 Probable and 18 Possible FH. Cascade testing has identified three younger, and one older FH individuals; amenable risk factors and target outcomes are available for feedback and action. Barriers included insufficient infrastructure, limited stakeholder involvement, time limitations impacting clinical care and data collection, poor recognition, awareness and referral, and limited cascade testing. Overcoming these required persistence, reorganizing clinical work, with some assistance from clinic nurses, forward planning to involve patients and raising FH awareness through presentations to various audiences.

Conclusions: During this year the register was established and is functional: awareness is being raised. Future steps will target process improvement for effectiveness and sustainability.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Biomarkers / blood
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / epidemiology
  • Cholesterol, LDL / blood*
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Hyperlipoproteinemia Type II* / blood
  • Hyperlipoproteinemia Type II* / drug therapy
  • Hyperlipoproteinemia Type II* / epidemiology
  • Hyperlipoproteinemia Type II* / genetics
  • Male
  • Malta / epidemiology
  • Middle Aged
  • Phenotype
  • Preliminary Data
  • Prognosis
  • Program Development
  • Program Evaluation
  • Registries*
  • Research Design*
  • Risk Factors
  • Young Adult

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Cholesterol, LDL